By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Figure out How to Remain Informed about the Most recent Open Record Extra Offers - 26 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- 3Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- 4Manual for Famous Beverages 2024
- 5Working out at the airport? Some fliers can already smell the sweat.
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- Finding the Force of Mentorship: Self-awareness Through Direction
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- Russia downs 16 drones heading for Moscow, mayor says
- The Force of Systems administration: Individual Examples of overcoming adversity
- Defense Minister Katz moves to extend IDF service to 36 months
- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
